Lynsey Corless
Research Subjects
Lynsey Corless has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Dianne Backhouse
Department of Gastroenterology, Hepatology & Endoscopy, Hull Royal Infirmary, Hull, UK
2 shared publications- Stephen Griffin
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
2 shared publications - Aamir Saifuddin
Department of Gastroenterology St Marks Hospital and Academic Institute, Gastroenterology London UK
1 shared publication - Aaron Singh Bancil
Department of Nutritional Sciences, King’s College London, London, UK
1 shared publication - Aditi Kumar
Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK
1 shared publication - Aijaz Ahmed
Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, USA
1 shared publication
Latest Publications
- Open Access
From ambition to delivery: why realistic research matters in UK gastroenterology and hepatology
- Open Access
- 11 September 2026
- Published by BMJ in Frontline Gastroenterology
Time for action: a research taskforce to accelerate research delivery and participation in UK gastroenterology and hepatology
Objective: There are significant and complex challenges impacting the successful delivery of gastroenterology/hepatology research in the UK. These limit participation, impede progress and reduce opportunities to develop the next generation of research leaders. To mitigate these challenges, research needs to be designed, funded and championed with greater recognition of the realities of the healthcare system it will be delivered in. Achieving this aim of realistic research requires coordinated collective effort of the gastroenterology/hepatology community. Design/method: The British Society of Gastroenterology (BSG) Research Committee, the British Association for Study of the Liver Research Development Group-BSG Liver Clinical Research Group and the Gastroenterology and Hepatology National Specialty Group for the National Institute of Health and Care Research Delivery Network have convened a multidisciplinary research delivery taskforce, which will focus on identifying practical barriers and implementing solutions to accelerate UK research delivery and participation. Results: Five pillars have been identified to frame taskforce activities, comprising: workforce development for gastroenterology/hepatology, realistic research, realistic funding, valuing research and improved infrastructure. Six immediate actions have been identified to be taken now to address the key barriers to research delivery and increase capacity and capability. These include both system-level changes to improve feasibility and capacity and supportive measures to strengthen engagement and enable participation across the multidisciplinary workforce. A set of metrics will evaluate progress. Conclusion: Realistic research is critical to securing a strong academic future for our specialty. The Research Delivery Taskforce has been created to drive forward this vision.
- 11 September 2026
- Published by BMJ in Frontline Gastroenterology
Open AccessTime for action: a research taskforce to accelerate research delivery and participation in UK gastroenterology and hepatology
Objective: There are significant and complex challenges impacting the successful delivery of gastroenterology/hepatology research in the UK. These limit participation, impede progress and reduce opportunities to develop the next generation of research leaders. To mitigate these challenges, research needs to be designed, funded and championed with greater recognition of the realities of the healthcare system it will be delivered in. Achieving this aim of realistic research requires coordinated collective effort of the gastroenterology/hepatology community. Design/method: The British Society of Gastroenterology (BSG) Research Committee, the British Association for Study of the Liver Research Development Group-BSG Liver Clinical Research Group and the Gastroenterology and Hepatology National Specialty Group for the National Institute of Health and Care Research Delivery Network have convened a multidisciplinary research delivery taskforce, which will focus on identifying practical barriers and implementing solutions to accelerate UK research delivery and participation. Results: Five pillars have been identified to frame taskforce activities, comprising: workforce development for gastroenterology/hepatology, realistic research, realistic funding, valuing research and improved infrastructure. Six immediate actions have been identified to be taken now to address the key barriers to research delivery and increase capacity and capability. These include both system-level changes to improve feasibility and capacity and supportive measures to strengthen engagement and enable participation across the multidisciplinary workforce. A set of metrics will evaluate progress. Conclusion: Realistic research is critical to securing a strong academic future for our specialty. The Research Delivery Taskforce has been created to drive forward this vision.
- Open Access
- 16 April 2025
- Published by BMJ in Frontline Gastroenterology
Decompensated cirrhosis: an update of the BSG/BASL admission care bundle
Acute decompensated cirrhosis (DC) and acute-on-chronic liver failure are common reasons for hospital admission that have a high in-hospital mortality rate (10%–20%). Patients require a detailed assessment for precipitating factors and management of complications such as infections, ascites, acute kidney injury and hepatic encephalopathy. Multiple reports have demonstrated unwarranted variability in the care of patients with DC. In 2014, the British Society of Gastroenterology (BSG)/British Association for the Study of the Liver (BASL) DC care bundle (DCCB) was introduced to provide a structured approach for the management of patients with DC in the first 24 hours. Usage of the DCCB has been shown to improve care of patients with DC. However, despite evidence indicating the beneficial impact of the DCCB, overall usage across the UK was only 11.4% in a national audit. Our aim was to update the DCCB to incorporate recent advances in care and improve its usability and develop a strategy to improve its usage nationally. The updated bundle was developed by a multidisciplinary group of specialists from BSG, BASL and the Society for Acute Medicine with the quality of evidence supporting the bundle recommendations assessed using the Grading of Recommendation Assessment Development and Evaluation tool. Proposed minimum standards for audit were also developed. Finally, a strategy to promote usage of the bundle including education/training at a national and local level, improving accessibility for the bundle, and promotion of frameworks for use at an institutional level to improve and monitor utilisation of DCCB.
- 16 April 2025
- Published by BMJ in Frontline Gastroenterology
Open AccessDecompensated cirrhosis: an update of the BSG/BASL admission care bundle
Acute decompensated cirrhosis (DC) and acute-on-chronic liver failure are common reasons for hospital admission that have a high in-hospital mortality rate (10%–20%). Patients require a detailed assessment for precipitating factors and management of complications such as infections, ascites, acute kidney injury and hepatic encephalopathy. Multiple reports have demonstrated unwarranted variability in the care of patients with DC. In 2014, the British Society of Gastroenterology (BSG)/British Association for the Study of the Liver (BASL) DC care bundle (DCCB) was introduced to provide a structured approach for the management of patients with DC in the first 24 hours. Usage of the DCCB has been shown to improve care of patients with DC. However, despite evidence indicating the beneficial impact of the DCCB, overall usage across the UK was only 11.4% in a national audit. Our aim was to update the DCCB to incorporate recent advances in care and improve its usability and develop a strategy to improve its usage nationally. The updated bundle was developed by a multidisciplinary group of specialists from BSG, BASL and the Society for Acute Medicine with the quality of evidence supporting the bundle recommendations assessed using the Grading of Recommendation Assessment Development and Evaluation tool. Proposed minimum standards for audit were also developed. Finally, a strategy to promote usage of the bundle including education/training at a national and local level, improving accessibility for the bundle, and promotion of frameworks for use at an institutional level to improve and monitor utilisation of DCCB.
- 17 March 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (6) , 468-477
Using data to enable growth of research capability and capacity: a retrospective longitudinal analysis of gastroenterology and hepatology research participation across secondary and tertiary healthcare settings within England
Objective Participation in clinical research confers tangible benefits for patients and healthcare organisations. Achieving adequate and representative recruitment into studies remains challenging, and variable recruitment rates between different hospitals and studies are well-known challenges. This study aims to characterise recruitment patterns across England’s secondary and tertiary care National Health Service (NHS) Trusts registered on the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) portfolio. Design/method Recruitment data submitted to the NIHR portfolio was extracted for all Gastroenterology and Hepatology studies that were actively recruiting between the period 1 April 2014 to 31 March 2024. All NHS Trusts within the UK were categorised into either secondary or tertiary care hospitals. We evaluated recruitment patterns, study distribution and temporal trends, comparing performance between secondary and tertiary sites, subspecialties and study designs. Results Of 346 hospital sites involved in study recruitment, 262 (76%) were secondary care hospitals and 84 (24%) were tertiary centres. A total of 853 studies were identified, with 485 (57%) being Gastroenterology-specific studies, recruiting 1 92 800 patients (79%), while Hepatology had 368 (43%) studies, recruiting 48 800 (21%) patients. Recruitment into Gastroenterology-specific studies was equally distributed between secondary and tertiary sites (51:49, p=0.69). 71% (pConclusion While Gastroenterology-specific studies showed similar recruitment volumes between secondary and tertiary care, recruitment into Hepatology studies remained predominantly from tertiary centres. Future work should focus on building Gastroenterology and Hepatology research delivery capability and capacity, while aligning with the recommendations from the Lord O’Shaughnessy report.
- 17 March 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (6) , 468-477
Using data to enable growth of research capability and capacity: a retrospective longitudinal analysis of gastroenterology and hepatology research participation across secondary and tertiary healthcare settings within England
Objective Participation in clinical research confers tangible benefits for patients and healthcare organisations. Achieving adequate and representative recruitment into studies remains challenging, and variable recruitment rates between different hospitals and studies are well-known challenges. This study aims to characterise recruitment patterns across England’s secondary and tertiary care National Health Service (NHS) Trusts registered on the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) portfolio. Design/method Recruitment data submitted to the NIHR portfolio was extracted for all Gastroenterology and Hepatology studies that were actively recruiting between the period 1 April 2014 to 31 March 2024. All NHS Trusts within the UK were categorised into either secondary or tertiary care hospitals. We evaluated recruitment patterns, study distribution and temporal trends, comparing performance between secondary and tertiary sites, subspecialties and study designs. Results Of 346 hospital sites involved in study recruitment, 262 (76%) were secondary care hospitals and 84 (24%) were tertiary centres. A total of 853 studies were identified, with 485 (57%) being Gastroenterology-specific studies, recruiting 1 92 800 patients (79%), while Hepatology had 368 (43%) studies, recruiting 48 800 (21%) patients. Recruitment into Gastroenterology-specific studies was equally distributed between secondary and tertiary sites (51:49, p=0.69). 71% (pConclusion While Gastroenterology-specific studies showed similar recruitment volumes between secondary and tertiary care, recruitment into Hepatology studies remained predominantly from tertiary centres. Future work should focus on building Gastroenterology and Hepatology research delivery capability and capacity, while aligning with the recommendations from the Lord O’Shaughnessy report.
- 26 December 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 272, 117104
Disposable and sensitive electrochemical magneto-immunosensor for point-of-care HCV diagnostics: Targeting HCVcAg, the active viremia biomarker, in patient samples
- 26 December 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 272, 117104
Disposable and sensitive electrochemical magneto-immunosensor for point-of-care HCV diagnostics: Targeting HCVcAg, the active viremia biomarker, in patient samples
- Open Access
- 22 September 2022
- Published by Wiley in Liver International
- Vol. 43 (2) , 308-316
Quality of end‐of‐life care with non‐malignant liver disease: Analysis of the VOICES National Survey of Bereaved People
Background and Aims: Patients with liver disease struggle to access palliative care. We aimed to compare carers' perceptions of end‐of‐life care for decedents with non‐malignant liver disease, malignant liver disease and other non‐malignant diseases, and to identify associated factors in non‐malignant liver disease.Methods: A retrospective analysis of individual‐level data from the National Survey of Bereaved People 2011–2015.Results: More decedents with non‐malignant liver disease died in hospital than other diseases (76.9% vs. 40.9% vs. 50.2%, p < .001), despite 89% wishing to die at home. Fewer decedents received home/hospice specialist palliative care compared with those with malignant liver disease (10.0% vs. 54.6%, p < .001). Carers of decedents with non‐malignant liver disease were less likely to rate overall end‐of‐life care quality as outstanding/excellent (29.3% vs. 43.9% vs. 42.3%, p < .001). For this group, poorer care was associated with younger (65–74 vs. 18–64 years, OR [odds ratio] 1.39, p = .01), more socially deprived decedents (OR .78, p = .02), and better care with greater social support (OR 1.82, p < .001) and community specialist palliative care involvement (OR 1.80, p < .001). There was no association between outstanding/excellent rating and underlying cause of non‐malignant liver disease (alcohol‐related vs. non‐alcohol‐related, p = .92) or place of death (hospital vs. non‐hospital, p = .476).Conclusions: End‐of‐life care could be improved by integrating hepatology and community services, particularly specialist palliative care, and advance care planning to facilitate care and death (where desired) at home. However, death in hospital may be appropriate for those with non‐malignant liver disease.
- 22 September 2022
- Published by Wiley in Liver International
- Vol. 43 (2) , 308-316
Open AccessQuality of end‐of‐life care with non‐malignant liver disease: Analysis of the VOICES National Survey of Bereaved People
Background and Aims: Patients with liver disease struggle to access palliative care. We aimed to compare carers' perceptions of end‐of‐life care for decedents with non‐malignant liver disease, malignant liver disease and other non‐malignant diseases, and to identify associated factors in non‐malignant liver disease.Methods: A retrospective analysis of individual‐level data from the National Survey of Bereaved People 2011–2015.Results: More decedents with non‐malignant liver disease died in hospital than other diseases (76.9% vs. 40.9% vs. 50.2%, p < .001), despite 89% wishing to die at home. Fewer decedents received home/hospice specialist palliative care compared with those with malignant liver disease (10.0% vs. 54.6%, p < .001). Carers of decedents with non‐malignant liver disease were less likely to rate overall end‐of‐life care quality as outstanding/excellent (29.3% vs. 43.9% vs. 42.3%, p < .001). For this group, poorer care was associated with younger (65–74 vs. 18–64 years, OR [odds ratio] 1.39, p = .01), more socially deprived decedents (OR .78, p = .02), and better care with greater social support (OR 1.82, p < .001) and community specialist palliative care involvement (OR 1.80, p < .001). There was no association between outstanding/excellent rating and underlying cause of non‐malignant liver disease (alcohol‐related vs. non‐alcohol‐related, p = .92) or place of death (hospital vs. non‐hospital, p = .476).Conclusions: End‐of‐life care could be improved by integrating hepatology and community services, particularly specialist palliative care, and advance care planning to facilitate care and death (where desired) at home. However, death in hospital may be appropriate for those with non‐malignant liver disease.
P92 The burden of socioeconomic deprivation amongst cirrhotic patients in England
Introduction There is an on-going public health crisis posed by liver disease, which disproportionately affects the poorest and most marginalised members of society. Our hospital is based in an area with one of the largest proportions of highly deprived neighbourhoods in England. As such, the prevalence of liver disease within this population is substantial. The aim of this study is to provide a descriptive analysis of deprivation within a cirrhosis surveillance database in a large tertiary teaching hospital in England. Method All patients diagnosed with advanced fibrosis and cirrhosis considered appropriate for surveillance at our centre, were entered into the database sequentially from April 2018 onwards. All patients were offered specialist Hepatology follow-up and attendance at clinic appointments was documented. Basic demographic details were recorded. Indices of multiple deprivation according to the 2019 iteration were determined using postcodes identified through electronic health records. Results 841 patients entered the database between April 2018 and October 2021. 36 patients died during follow up and 5 patients moved out of area. of the remaining 800 patients, 40% of the cohort were female. Median age was 60 years (range 26-91 years). 46% of the cohort had alcohol related liver disease, 21% non-alcoholic fatty liver disease, 14% viral hepatitis. 63% of patients had either Childs-Pugh (CP) A or advanced fibrosis, 14% CP-B and 3% CP-C. 21% had no staging recorded. During 2021, 25% of appointments in the liver clinic were not attended, in comparison to a national yearly average of 11%. 35% of the cohort lived within the most deprived decile and in total over 60% lived within the lowest four deciles, with a similar pattern observed within other domains of deprivation, including income, employment, education and crime. Patients were analysed according to underlying aetiology, with almost half of patients with viral hepatitis living in the lowest deprivation decile (Figure 1). Whilst there was a small number of CP-C patients, disease severity mirrored the expected deprivation distribution, with the majority of patients with more advanced disease living in areas of greater deprivation. Conclusion The patterns of deprivation observed in the cirrhosis database are reflected in population level data from the region. 80% of the cohort have liver disease due to preventable causes and engagement with out-patient services was poor with one quarter of appointments not attended. This study demonstrates the true burden of liver disease amongst those living in the most deprived districts of England, and highlights the need for robust public health measures to engage this patient group and reduce premature mortality from liver disease.
P92 The burden of socioeconomic deprivation amongst cirrhotic patients in England
Introduction There is an on-going public health crisis posed by liver disease, which disproportionately affects the poorest and most marginalised members of society. Our hospital is based in an area with one of the largest proportions of highly deprived neighbourhoods in England. As such, the prevalence of liver disease within this population is substantial. The aim of this study is to provide a descriptive analysis of deprivation within a cirrhosis surveillance database in a large tertiary teaching hospital in England. Method All patients diagnosed with advanced fibrosis and cirrhosis considered appropriate for surveillance at our centre, were entered into the database sequentially from April 2018 onwards. All patients were offered specialist Hepatology follow-up and attendance at clinic appointments was documented. Basic demographic details were recorded. Indices of multiple deprivation according to the 2019 iteration were determined using postcodes identified through electronic health records. Results 841 patients entered the database between April 2018 and October 2021. 36 patients died during follow up and 5 patients moved out of area. of the remaining 800 patients, 40% of the cohort were female. Median age was 60 years (range 26-91 years). 46% of the cohort had alcohol related liver disease, 21% non-alcoholic fatty liver disease, 14% viral hepatitis. 63% of patients had either Childs-Pugh (CP) A or advanced fibrosis, 14% CP-B and 3% CP-C. 21% had no staging recorded. During 2021, 25% of appointments in the liver clinic were not attended, in comparison to a national yearly average of 11%. 35% of the cohort lived within the most deprived decile and in total over 60% lived within the lowest four deciles, with a similar pattern observed within other domains of deprivation, including income, employment, education and crime. Patients were analysed according to underlying aetiology, with almost half of patients with viral hepatitis living in the lowest deprivation decile (Figure 1). Whilst there was a small number of CP-C patients, disease severity mirrored the expected deprivation distribution, with the majority of patients with more advanced disease living in areas of greater deprivation. Conclusion The patterns of deprivation observed in the cirrhosis database are reflected in population level data from the region. 80% of the cohort have liver disease due to preventable causes and engagement with out-patient services was poor with one quarter of appointments not attended. This study demonstrates the true burden of liver disease amongst those living in the most deprived districts of England, and highlights the need for robust public health measures to engage this patient group and reduce premature mortality from liver disease.
- Open Access
- 15 September 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (5) , 181-183
Issue Information
GastroHep is a journal published by Wiley. It is an international, peer reviewed, quality publication focusing on current and cutting edge research in academic and clinical gastroenterology and hepatology.
- 15 September 2020
- Published by Hindawi Limited in GastroHep
- Vol. 2 (5) , 181-183
Open AccessIssue Information
GastroHep is a journal published by Wiley. It is an international, peer reviewed, quality publication focusing on current and cutting edge research in academic and clinical gastroenterology and hepatology.
- Open Access
- 3 June 2020
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 29 (2) , 235-245
Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main indicator of associated morbidity and mortality outcomes. Therefore, identifying patients with, or at risk of, advanced fibrosis due to NASH and linking them to appropriate care is critical. This can be challenging due to a lack of awareness of NASH among healthcare professionals and a lack of standardised protocols for identifying patients. Simple noninvasive tests may provide an opportunity to facilitate early identification of these patients. This article proposes a simple, universally applicable diagnostic algorithm for use in clinical practice, that includes sequential use of noninvasive tests, ideally a biological marker and an imaging technique, which may help to facilitate early diagnosis of these patients. In the opinion of the authors, early detection of advanced fibrosis is fundamental in the efforts to halt the progression of NASH and diagnostic algorithms may facilitate pre-emptive interventions to curtail the disease.
- 3 June 2020
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 29 (2) , 235-245
Open AccessIdentification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main indicator of associated morbidity and mortality outcomes. Therefore, identifying patients with, or at risk of, advanced fibrosis due to NASH and linking them to appropriate care is critical. This can be challenging due to a lack of awareness of NASH among healthcare professionals and a lack of standardised protocols for identifying patients. Simple noninvasive tests may provide an opportunity to facilitate early identification of these patients. This article proposes a simple, universally applicable diagnostic algorithm for use in clinical practice, that includes sequential use of noninvasive tests, ideally a biological marker and an imaging technique, which may help to facilitate early diagnosis of these patients. In the opinion of the authors, early detection of advanced fibrosis is fundamental in the efforts to halt the progression of NASH and diagnostic algorithms may facilitate pre-emptive interventions to curtail the disease.